Guanhao Biotech Co Ltd (300238) — Working Capital to Net Assets Ratio
Guanhao Biotech Co Ltd (300238) has a Working Capital to Net Assets ratio of 31.2% as of March 2026. Working capital of CN¥154.24 Million (current assets of CN¥307.84 Million minus current liabilities of CN¥153.60 Million) is measured against net assets of CN¥494.91 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Guanhao Biotech Co Ltd to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Guanhao Biotech Co Ltd Working Capital to Net Assets (2007–2025)
This chart shows how Guanhao Biotech Co Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 31.2%, reflecting working capital of CN¥154.24 Million against net assets of CN¥494.91 Million CNY. For the complete balance sheet picture, see balance sheet size of Guanhao Biotech Co Ltd.
Annual Working Capital to Net Assets for Guanhao Biotech Co Ltd (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Guanhao Biotech Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check asset resilience ratio of Guanhao Biotech Co Ltd to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 27.1% | CN¥137.07 Million | CN¥506.03 Million | CN¥325.61 Million | CN¥188.54 Million | ▲ +8.3 pp |
| 2024 | 18.8% | CN¥87.80 Million | CN¥467.59 Million | CN¥265.79 Million | CN¥177.99 Million | ▼ -1.9 pp |
| 2023 | 20.7% | CN¥94.56 Million | CN¥456.26 Million | CN¥267.28 Million | CN¥172.72 Million | ▼ -4.8 pp |
| 2022 | 25.5% | CN¥109.90 Million | CN¥430.88 Million | CN¥298.89 Million | CN¥188.99 Million | ▲ +2.4 pp |
| 2021 | 23.1% | CN¥173.14 Million | CN¥748.16 Million | CN¥435.41 Million | CN¥262.27 Million | ▲ +4.3 pp |
| 2020 | 18.9% | CN¥135.33 Million | CN¥716.66 Million | CN¥438.03 Million | CN¥302.70 Million | ▼ -1.5 pp |
| 2019 | 20.4% | CN¥143.85 Million | CN¥704.14 Million | CN¥416.28 Million | CN¥272.43 Million | ▲ +9.1 pp |
| 2018 | 11.3% | CN¥130.57 Million | CN¥1.16 Billion | CN¥401.57 Million | CN¥271.00 Million | ▼ -7.8 pp |
| 2017 | 19.1% | CN¥231.49 Million | CN¥1.21 Billion | CN¥527.92 Million | CN¥296.43 Million | ▼ -3.0 pp |
| 2016 | 22.1% | CN¥322.04 Million | CN¥1.46 Billion | CN¥500.41 Million | CN¥178.37 Million | ▼ -18.7 pp |
| 2015 | 40.8% | CN¥253.25 Million | CN¥620.62 Million | CN¥389.66 Million | CN¥136.41 Million | ▼ -7.2 pp |
| 2014 | 48.0% | CN¥255.03 Million | CN¥531.61 Million | CN¥285.33 Million | CN¥30.30 Million | ▼ -5.2 pp |
| 2013 | 53.2% | CN¥264.78 Million | CN¥498.16 Million | CN¥292.66 Million | CN¥27.88 Million | ▼ -2.2 pp |
| 2012 | 55.3% | CN¥251.22 Million | CN¥454.11 Million | CN¥284.44 Million | CN¥33.23 Million | ▼ -17.0 pp |
| 2011 | 72.3% | CN¥312.90 Million | CN¥432.79 Million | CN¥329.70 Million | CN¥16.80 Million | ▲ +20.1 pp |
| 2010 | 52.2% | CN¥75.74 Million | CN¥144.99 Million | CN¥117.63 Million | CN¥41.89 Million | ▼ -6.1 pp |
| 2009 | 58.3% | CN¥44.87 Million | CN¥76.95 Million | CN¥50.81 Million | CN¥5.94 Million | ▲ +29.7 pp |
| 2008 | 28.6% | CN¥10.60 Million | CN¥37.01 Million | CN¥21.72 Million | CN¥11.12 Million | ▼ -27.4 pp |
| 2007 | 56.0% | CN¥11.58 Million | CN¥20.67 Million | CN¥29.72 Million | CN¥18.14 Million | — |